Zeria Pharmaceutical Co., Ltd. (4559.T) Stock
Zeria Pharmaceutical Co., Ltd.

Company profile
Its largest business segment, Ethical Pharmaceutical Business, brought in 67% of segment revenue in fiscal year 2025; Japan was the largest region with 43%. Zeria Pharmaceutical reports about 1,748 full-time employees.
What stands out
- Revenue and net income in fiscal year 2025 were the highest of the last 4 fiscal years.
Figures from company filings; latest fiscal year ended March 31, 2026.
About Zeria Pharmaceutical Co., Ltd.
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.
Largest shareholders
- Zeria Pharmaceutical Co., Ltd.16.04%
- Ibe Family10.63 %10.63%
- Mitsubishi Ufj Financial Group, Inc.5.27%
- Sumitomo Mitsui Financial Group, Inc.4.60%
- Sachiaki Ibe3.176 %3.18%
Share of the company, as of September 25, 2026
Leadership
- Sachiaki Ibe — Chairman & CEO, 84
- Mitsuhiro Ibe — President, COO & Representative Director, 54
- Yasuhisa Tanaka — Executive Officer and GM of Finance & Accounting Division
- Yuuki Okazawa — Senior Managing Executive Officer, Director of Administrative & Personnel and Director, 60
- Yoshihiro Hiraga — Executive Officer and GM of Research & Development Headquarters, Licensing Office, 68
What is Zeria Pharmaceutical's largest business segment?
Ethical Pharmaceutical Business, with 58.98 billion JPY or 67% of segment revenue in fiscal year 2025. Next: Consumer Health Care Business (32%) and Others (1%).
Where does Zeria Pharmaceutical make most of its revenue?
Japan: 43% of revenue by region in fiscal year 2025, followed by Other Europe (27%).
What companies are similar to Zeria Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Kaken Pharmaceutical Co., Ltd. (4521.T), Katakura Industries Co.,Ltd. (3001.T), Mochida Pharmaceutical Co., Ltd. (4534.T), Kyorin Pharmaceutical Co., Ltd. (4569.T).
How has Zeria Pharmaceutical's revenue changed over the last 4 fiscal years?
Revenue by fiscal year: FY2022, 59.53 billion JPY; FY2023, 68.38 billion JPY; FY2024, 75.73 billion JPY; FY2025, 87.31 billion JPY.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Zeria Pharmaceutical Co., Ltd. (4559.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4559.T